| Dr Kris Francis Kobalter, MD | |
|
945 Goethals Drive Suite 200, Kadlec Clinic Associated Physicians For Women, Richland, WA 99352 | |
| (509) 942-3627 | |
| (509) 942-2340 |
| Full Name | Dr Kris Francis Kobalter |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 34 Years |
| Location | 945 Goethals Drive Suite 200, Richland, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255302972 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | G69005 (California) | Secondary |
| 207V00000X | Obstetrics & Gynecology | MD60329790 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kadlec Regional Medical Center | Richland, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kadlec Regional Medical Center | 9739098617 | 338 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A temporary suspension of the initial dose of hepatitis B vaccine appears to have contributed to fewer newborns being vaccinated for hepatitis B in 2000 than in 1998, according to a study published in the May 19 issue of the Journal of the American Medical Association (JAMA).
Stem Cell Innovations announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.
Following the news that the US Food and Drug Administration (FDA) has recommended emergency approval for the Pfizer-BioNTech COVID-19 vaccine and that the US has reported its highest one-day COVID-19 death tally;
The Los Angeles Times examines how "activists in Washington, and Thailand and other developing countries are accusing the Obama administration of endangering access to affordable drugs to fight AIDS and other epidemic diseases."
› Verified 5 days ago
| Entity Name | Kadlec Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972507580 PECOS PAC ID: 9739098617 Enrollment ID: O20031104000035 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A temporary suspension of the initial dose of hepatitis B vaccine appears to have contributed to fewer newborns being vaccinated for hepatitis B in 2000 than in 1998, according to a study published in the May 19 issue of the Journal of the American Medical Association (JAMA).
Stem Cell Innovations announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.
Following the news that the US Food and Drug Administration (FDA) has recommended emergency approval for the Pfizer-BioNTech COVID-19 vaccine and that the US has reported its highest one-day COVID-19 death tally;
The Los Angeles Times examines how "activists in Washington, and Thailand and other developing countries are accusing the Obama administration of endangering access to affordable drugs to fight AIDS and other epidemic diseases."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kris Francis Kobalter, MD 3900 S Zintel Way, Kennewick, WA 99338 Ph: (509) 942-3627 | Dr Kris Francis Kobalter, MD 945 Goethals Drive Suite 200, Kadlec Clinic Associated Physicians For Women, Richland, WA 99352 Ph: (509) 942-3627 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A temporary suspension of the initial dose of hepatitis B vaccine appears to have contributed to fewer newborns being vaccinated for hepatitis B in 2000 than in 1998, according to a study published in the May 19 issue of the Journal of the American Medical Association (JAMA).
Stem Cell Innovations announced today that the Company has signed a Master Services Agreement to provide research and assay services in support of Agennix's talactoferrin program. The assay utilizes SCLL's C3A human liver cell line.
Following the news that the US Food and Drug Administration (FDA) has recommended emergency approval for the Pfizer-BioNTech COVID-19 vaccine and that the US has reported its highest one-day COVID-19 death tally;
The Los Angeles Times examines how "activists in Washington, and Thailand and other developing countries are accusing the Obama administration of endangering access to affordable drugs to fight AIDS and other epidemic diseases."
› Verified 5 days ago
Kenton L. Sizemore, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 945 Goethals Drive, Suite 200, Richland, WA 99352 Phone: 509-942-3627 Fax: 509-942-2340 | |
Zaid Mohammed Diken, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 969 Stevens Dr Ste 3a, Richland, WA 99352 Phone: 509-946-8696 Fax: 509-946-8646 | |
Dr. Candace C Green, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2630 N Columbia Center Blvd, Suite B, Richland, WA 99352 Phone: 509-420-5053 Fax: 509-492-5537 | |
Dr. Alexis Xiaowei Tuck, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 945 Goethals Dr, Richland, WA 99352 Phone: 509-942-3095 | |
Hipolito Mance Custodio Iii, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 945 Goethals Dr, Suite 200, Richland, WA 99352 Phone: 509-942-2555 Fax: 509-942-2340 | |
Dr. Richard C Lorenzo Jr., D.O Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1045 Jadwin Ave, Richland, WA 99352 Phone: 509-392-6700 Fax: 509-392-6699 |